Sichuan Huaxin (Group) Certified Public Accountants
Address: 28th floor, jinmaolidu south, No. 18, Ximianqiao street, Chengdu (special general partnership) Tel: (028) 85560449
Fax: (028) 85560449
Si Chuan Hua Xin (Group) CPA 610041
Email: [email protected].
(LLP)
Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Assurance report on the deposit and use of raised funds in 2021
Chxs (2022) No. 0112
catalog:
1. Anti counterfeiting identification
2. Text of special report
3. Annexes
Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Assurance report on the deposit and use of raised funds in 2021
Chuan Hua Xin Zhuan (2022) No. 0112 Chongqing Lummy Pharmaceutical Co.Ltd(300006) all shareholders:
We have accepted the entrustment to verify the attached special report of Chongqing Lummy Pharmaceutical Co.Ltd(300006) (hereinafter referred to as the “special report of raised funds”) prepared by Chongqing Lummy Pharmaceutical Co.Ltd(300006) on the deposit and use of raised funds in 2021 (hereinafter referred to as the “special report of raised funds”).
1、 Use and purpose of the report
This assurance report is only for the purpose of your company’s annual report disclosure and shall not be used for any other purpose. We agree to take this assurance report as a necessary document for your company’s annual report, submit it together with other documents and disclose it to the public.
2、 Responsibilities of the board of directors
The responsibility of the board of directors of your company is to prepare a special report on raising funds in accordance with the provisions of the CSRC’s guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) (CSRC announcement [2022] No. 15) and the Shenzhen Stock Exchange’s self regulatory guidelines for listed companies No. 2 – standardized operation of companies listed on the gem (SZS [2022] No. 14), And ensure that the contents of the special report on raised funds are true, accurate and complete, and there are no false records, misleading statements or major omissions.
3、 Responsibilities of Certified Public Accountants
Our responsibility is to publish the assurance conclusion on the special report of your company’s raised funds on the basis of the implementation of the assurance work.
4、 Job overview
We have carried out the assurance business in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information. The standard requires us to plan and implement assurance work to obtain reasonable assurance on whether the information of the assurance object is free from material misstatement. In the process of assurance, we have implemented the necessary procedures including understanding, inquiry, inspection and so on. We believe that the assurance evidence we have obtained is sufficient and appropriate, which provides a reasonable basis for the publication of conclusions.
5、 Assurance conclusion
We believe that the preparation of the special report on the raised funds of your company complies with the provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies (revised in 2022) (CSRC announcement [2022] No. 15) and the guidelines for the self-discipline supervision of listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on the gem (SZS [2022] No. 14), It truthfully reflects the actual deposit and use of the raised funds of your company in 2021 in all major aspects.
Attachment: Chongqing Lummy Pharmaceutical Co.Ltd(300006) special report on the deposit and use of raised funds in 2021 Sichuan Huaxin (Group) certified public accountants China Certified Public Accountant: Chen Jie
(special general partnership)
Chengdu, China Certified Public Accountant: Li Youming
Chinese certified public accountant: Zhao Xiangyu
March 24, 2002
Special report on the deposit and use of Chongqing Lummy Pharmaceutical Co.Ltd(300006) raised funds
Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Special report on the deposit and use of raised funds in 2021
In accordance with the relevant provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies and the guidelines for the self discipline supervision of listed companies No. 2 – standardized operation of companies listed on the gem issued by the CSRC, the company will make a special explanation on the deposit and use of raised funds in 2021 as follows:
1、 Availability of raised funds
According to the reply on Approving the registration of Chongqing Lummy Pharmaceutical Co.Ltd(300006) issuing shares to specific objects (zjxk [2021] No. 437) issued by China Securities Regulatory Commission, the company reported to Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) Nanning Zhongheng Tongde pharmaceutical industry investment fund partnership (limited partnership) and Guangxi guangtou Guohong health industry fund partnership (limited partnership) issued 24367000 ordinary shares (A shares) in total, with a par value of 1.00 yuan per share and an issue price of 4.45 yuan / share. The total amount of funds actually raised was 108433150000 yuan. After deducting various issuance expenses of 1981560459 yuan, The net amount of funds raised is RMB 106451589541 (hereinafter referred to as “funds raised by issuing shares to specific objects in 2021”).
The above raised funds were received on March 2, 2021. The availability of the raised funds has been verified by Sichuan Huaxin (Group) Certified Public Accountants (special general partnership) and issued the capital verification report “Chuan Hua Xin Yan (2021) No. 0021”.
2、 Use and balance of raised funds
1. Non public offering of shares in 2021
As of December 31, 2021, the use and balance of funds raised by the company’s issuance of shares to specific objects in 2021 are as follows (monetary unit: RMB):
Project amount
Actually transferred into the raised funds of the company [Note 1] 106606652750
Less: 96397824673 directly invested in the raised project funds
Other issuance expenses paid: 155063209
Plus: net interest income deducting handling charges 487604384
Balance of special account for raised funds 10541369252
[Note 1]: the total amount of funds raised by the company from issuing shares to specific objects is 108433150000 yuan, Sinolink Securities Co.Ltd(600109) shares
Special report on the deposit and use of Chongqing Lummy Pharmaceutical Co.Ltd(300006) raised funds
On March 2, 2021, the company transferred the balance of RMB 106606652750 after deducting the recommendation and underwriting fee of RMB 1826497250 (excluding tax) to the special account for raised funds opened by the company.
2. As of December 31, 2021, the deposit of funds raised by non-public offering of the company in 2021 is shown in the following table (monetary unit: RMB):
Opening bank account number, account category and purpose year-end balance
Hua Xia Bank Co.Limited(600015) current account
Chongqing Liangjiang Jinkai sub branch 112830 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 2978 supplementary working capital 541363393 Hua Xia Bank Co.Limited(600015) capital
112830 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 3234 certificate of deposit account [note] 10000000000 Chongqing Liangjiang Jinkai sub branch
Repayment account of Pudong Development Bank 10083008
Chongqing Branch Co., Ltd. 58.59 81
Total 10541369252
Note: according to the tripartite supervision agreement on raising funds by issuing shares to specific objects signed by the company, Hua Xia Bank Co.Limited(600015) Chongqing branch and Sinolink Securities Co.Ltd(600109) Chongqing Branch, the company deposited 330 million yuan of raised funds in the special account of Hua Xia Bank Co.Limited(600015) raised funds in the form of certificate of deposit. During the reporting period, the company transferred the raised funds from the certificate of deposit account to the special current account according to the needs of business activities, and used them to supplement working capital. By the end of 2021, the balance of the certificate of deposit account was 100 million yuan.
2、 Management of raised funds
In order to standardize and strengthen the management and use of raised funds and protect the legitimate rights and interests of investors, the company has formulated the raised funds management system in accordance with the provisions and requirements of relevant laws, regulations and normative documents. After the funds raised by this offering were received, the company hired a capital verification institution to verify the availability, and timely signed a supervision agreement on the raised funds with the sponsor and the relevant special account storage bank, so as to supervise the management and use of the raised funds and ensure the special use of the special funds.
3、 Actual use of raised funds this year
The comparison table of the company’s use of raised funds in 2021 is detailed in the annex to this report.
4、 Change the use of funds for investment projects with raised funds
As of December 31, 2021, the company has not changed the investment projects of the raised funds by issuing shares to specific objects in 2021.
5、 Use and disclosure of raised funds
The company uses the raised funds in strict accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the guidelines for self discipline supervision of listed companies No. 2 – standardized operation of GEM listed companies and other relevant laws and regulations, as well as the provisions and requirements of relevant laws and regulations of the CSRC and the management system of raised funds, and timely Truthfully, accurately and completely perform relevant information disclosure, and there is no illegal use of raised funds.
Special report on the deposit and use of Chongqing Lummy Pharmaceutical Co.Ltd(300006) raised funds
Annex 1: comparison table of the use of funds raised by issuing shares to specific objects in 2021
Chongqing Lummy Pharmaceutical Co.Ltd(300006) March 24, 2022
Chongqing Lummy Pharmaceutical Co.Ltd(300006) comparison of the use of funds raised by issuing shares to specific objects in 2021
